Back to News
Oct 14, 2025 4:00 PM

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE:TAK).

Under the terms of the agreement, Nabla Bio will receive double-digit millions in upfront and research cost payments and is eligible to receive success-based payments that may exceed $1 billion.

This second collaboration will deploy Nabla Bio's biomolecular design platform, Joint Atomic Model (JAM), across Takeda's early-stage development programs.

The new collaboration will include de novo design of antibodies in parallel for multiple targets, multispecifics, challenging targets, and other custom therapeutics.

Also Read: